{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T18:02:15Z","timestamp":1771351335787,"version":"3.50.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10072-025-08735-1","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:48:58Z","timestamp":1768974538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report: hypophosphatemia as a rare cause of tremor in a 29-year-old female patient"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7066-7749","authenticated-orcid":false,"given":"Milan","family":"Zimmermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludger","family":"Sch\u00f6ls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"8735_CR1","doi-asserted-by":"publisher","first-page":"g3172","DOI":"10.1136\/bmj.g3172","volume":"348","author":"P Glendenning","year":"2014","unstructured":"GlendenningP, Bell DA, Clifton-Bligh RJ (2014) Investigating hypophosphataemia. BMJ 348:g3172 https:\/\/doi.org\/10.1136\/bmj.g3172","journal-title":"BMJ"},{"issue":"10","key":"8735_CR2","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.amjmed.2005.02.014","volume":"118","author":"A Gaasbeek","year":"2005","unstructured":"GaasbeekA, Meinders AE (2005) Hypophosphatemia: an update on its etiology and treatment. Am J Med 118(10):1094\u20131101 https:\/\/doi.org\/10.1016\/j.amjmed.2005.02.014","journal-title":"Am J Med"},{"issue":"8471","key":"8735_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/s0140-6736(86)91926-4","volume":"1","author":"J Vanneste","year":"1986","unstructured":"Vanneste J, Hage J (1986) Acute severe hypophosphataemia mimicking Wernicke\u2019s encephalopathy. Lancet 1(8471): 44. https:\/\/doi.org\/10.1016\/s0140-6736(86)91926-4","journal-title":"Lancet"},{"issue":"6","key":"8735_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s40620-020-00963-2","volume":"34","author":"NK Younis","year":"2021","unstructured":"YounisNK, Maktabi MAN, Jdiaa SS, Koubar SH (2021) A case of severe hypophosphatemia. J Nephrol 34(6):2117\u20132121 https:\/\/doi.org\/10.1007\/s40620-020-00963-2","journal-title":"J Nephrol"},{"issue":"1","key":"8735_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005792-200001000-00001","volume":"79","author":"R Subramanian","year":"2000","unstructured":"SubramanianR, Khardori R (2000) Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment. Med (Baltim) 79(1):1\u20138 https:\/\/doi.org\/10.1097\/00005792-200001000-00001","journal-title":"Med (Baltim)"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08735-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08735-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08735-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T17:03:40Z","timestamp":1771347820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08735-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["8735"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08735-1","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest in relation to the manuscript.Dr. Milan Zimmermann has received a research grant from the University of Tuebingen (Clinician Scientist; Project-Nr. 481-0-0).Ludger Sch\u00f6ls received funding by the German Research council (DFG grant SCHO754\/6\u2009\u2212\u20092), German Ministry of Health (BMG grant ZMVI1- 2520DAT94E to LeukoExpert), German Ministry of Education and Research (BMBF grant 01GM1905A to Treat HSP and grant 01GM1907A to Treat ION), European Commission (EU grant 947588 to the ERN-RND registry and JPND grant 01ED16028 to ESMI) and is a member of the European Reference Network for Rare Neurological Diseases (Project No 739510). He served as advisor for Alexion, Novartis and Vico. He participates as a principal investigator in clinical studies sponsored by Vigil Neuroscience (VGL101-01.001; VGL101-01.002), Vico Therapeutics (VO659-CT01), PTC Therapeutics (PTC743-NEU-003-FA) and Stealth BioTherapeutics (SPIMD-301). All disclosures are unrelated to the present manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}